Literature DB >> 25995874

Crystal structure of bis-[4-(1H-pyrrol-1-yl)phen-yl] ferrocene-1,1'-di-carboxyl-ate: a potential chemotherapeutic drug.

Wanda I Pérez1, Arnold L Rheingold2, Enrique Meléndez1.   

Abstract

The title iron(II) complex, [Fe(C16H12NO2)2], crystallizes in the ortho-rhom-bic space group Pbca with the Fe(2+) cation positioned on an inversion center. The cyclo-penta-dienyl (Cp) rings adopt an anti conformation in contrast with other substituted ferrocenes in which the Cp rings appear in a nearly eclipsed conformation. The Cp and the aromatic rings are positioned out of the plane, with a twist angle of 70.20 (12)°, and the C(Cp)-C(CO) bond length is shorter than a typical C-C single bond, which suggests a partial double-bond character and delocalization with the Cp π system. The structure of the complex is compared to other functionalized ferrocenes synthesized in our laboratory.

Entities:  

Keywords:  MCF-7; anti­proliferative; chemotherapeutic drug; crystal structure; disubstituted ferrocene; pyrrole

Year:  2015        PMID: 25995874      PMCID: PMC4420060          DOI: 10.1107/S2056989015007446

Source DB:  PubMed          Journal:  Acta Crystallogr E Crystallogr Commun


Chemical context

The gold standard of treatment for breast cancer has traditionally been cisplatin, a metal-based agent. Its administration, alone or in combination with other drugs, is also highly effective against various other types of cancers, including ovarian, head and neck, bladder, testicular and lung cancers (Galanski et al., 2005 ▸; Sandler et al., 2011 ▸). However, its clinical use suffers from major drawbacks, such as severe toxic side effects including neurotoxicity, hepatotoxicity, and nephrotoxicity (Pabla & Dong, 2008 ▸), as well as a drug-resistance phenomenon which leads to unsuccessful treatment (Dempke et al., 2000 ▸). Consequently, other metal-based drugs have been investigated, among them ferrocenes (Köpf-Maier et al., 1984 ▸). Ferrocene has the versatility of easy functionalization providing a fertile field for structural modification and to study structure–activity relationship (SAR). Our group has been working in this field for many years, leading to exciting and biologically active ferrocenes. A wide variety of pendant (functional) groups have been attached or linked to the Cp ring to tailor the anti-proliferative properties of ferrocene, many of them with great success (Braga & Silva, 2013 ▸; Gasser et al., 2011 ▸; Jaouen & Metzler-Nolte, 2010 ▸; Fouda et al., 2007 ▸; Jaouen, 2006 ▸; van Staveren & Metzler-Nolte, 2004 ▸; Nguyen et al., 2009 ▸; Top et al., 2003 ▸; Vessières et al., 2005 ▸, 2006 ▸; Meléndez, 2012 ▸; Vera et al., 2011 ▸, 2014 ▸). Lately, a new range of organic chemotherapeutic compounds have been studied using pyrrole derivatives. These pyrrole derivatives have revealed good anti-proliferative activity and an increase in membrane permeability, allowing the compounds to reach the nucleus (Ghorab et al., 2014 ▸; Abou El Ella et al., 2008 ▸; Chatzopoulou et al., 2014 ▸; Mohamed et al., 2013 ▸; Hassan et al., 2009 ▸; Esteves et al., 2010 ▸; Clark et al., 2007 ▸; Merighi et al., 2003 ▸). Therefore, we functionalized ferrocene with a pyrrole, 4-(1H-pyrrol-1-yl)phenol, obtaining three new ferrocenes: 1,1′-4-(1H-pyrrol-1-yl)phenyl ferrocenedi­carboxyl­ate, 1,4-(1H-pyrrol-1-yl)phenyl, 1′-carboxyl ferrocene­carboxyl­ate (Fc-(CO2-Ph-4-Py)CO2H) and 4-(1H-pyrrol-1-yl)phenyl ferro­cene­acetyl­ate (Fc-CH2CO2-Ph-4-Py). We investigated their biological activities on breast cancer cell line (MCF-7) and among these ferrocenes, 1,1′-4-(1H-pyrrol-1-yl)phenyl ferrocenedi­carboxyl­ate (I) was shown to be most active in this series (Pérez et al., 2015 ▸). Nevertheless, the solid-state structure of (I) has been elusive (Pérez et al., 2015 ▸). The importance of this complex is the incorporation of pyrrole groups, which are derivatives of biologically active compounds, as well as pyrrole being an electrochemically active group precursor of polymeric mat­erial. In addition, ferrocene anti­cancer activity has been associated with its redox behavior and the capability to produce reactive oxygen species (ROS) (Acevedo et al., 2012 ▸; Kovjazin et al., 2003 ▸; Tabbi et al., 2002 ▸; Osella et al., 2005 ▸). Thus, the attachment of an electrochemically active group on ferrocene could potentiate the production of ROS and enhance its anti­cancer activity. Given that the solid-state structure of this complex is not available, we determined the crystal structure of bis­[4-(1H-pyrrol-1-yl)phen­yl] ferrocene-1,1′-di­carboxyl­ate, (I). Additionally, we compared the obtained crystal structure with other functionalized ferrocenes synthesized in our laboratory viz.: 4-bromo­phenyl (II) and 4-chloro­phenyl ferrocene­carboxyl­ate (III) (Vera et al., 2014 ▸), and 1,1′-methyl ferrocenedi­carboxyl­ate (IV) (Gao et al., 2009 ▸).

Structural commentary

The asymmetric unit contains one half-mol­ecule since Fe2+ lies on an inversion center, Fig. 1 ▸. This symmetry is implied by the NMR data where only one set of signals were found for H2/H5 and H3/H4 of the Cp rings, as well as the H2/H6 and H3/H5 of the phenyl and H2/H5 and H3/H4 of the pyrrole groups. Consequently, the Cp rings adopt a perfect anti conformation. The average FeC(Cp) bond length is 2.044 (10) Å, which is very similar to that reported for ferrocene (Dunitz et al., 1956 ▸) and other structures previously reported by our lab (Vera et al., 2014 ▸; Gao et al., 2009 ▸). The FeC bond length of the substituted carbon [Fe—C1 2.032 (2) Å] is shorter that the remaining FeC bond lengths due to the inductive effect of the carboxyl­ate on the Cp ring. The twist angles between the Cp ring and the carboxyl­ate and the Cp ring and the aromatic ring are 14.4 (3)° (above the Cp plane) and 70.20 (12)°, respectively.
Figure 1

The mol­ecular structure of (I), with displacement ellipsoids drawn at the 30% probability level. Unlabelled atoms are related to labelled ones by the symmetry operation −x, −y, −z.

To put it in perspective, we compare (I) with previously synthesized ferrocenes in our group containing only one Cp functionalized and a phenyl group attached to the carboxyl­ate, but with Br and Cl instead of pyrrole in the 4-position, (II) and (III) (CCDC 949002 and 949003, Vera et al., 2014 ▸). First, in the 4-bromo­phenyl and 4-chloro­phenyl derivatives, the Cp rings are positioned in a nearly eclipsed conformation and parallel with stagger angles < 3° and Cp tilt angles of 0.48–1.25°. In contrast, (I) has a perfect anti conformation. The carbonyl carbon of (I) has a distorted trigonal–planar geometry, analogous to the 4-chloro­phenyl and 4-bromo­phenyl ferrocene­carboxyl­ates. The twist angles between the Cp ring and the carboxyl­ate for 4-bromo and 4-chloro­phenyl ferrocene­carboxyl­ates (6.75–10.15°) are smaller than that of the subject complex, 14.4 (3)°. Additionally, as mentioned previously, the carbonyl oxygen of (I) lies above the Cp plane whereas for the bromo and chloro derivatives, the carbonyl oxygens lie below the Cp plane. The twist angle between the Cp and the aromatic ring is 70.20 (12)° in (I), while in (II) and (III) the two rings are positioned at higher angles, approaching a perpendicular position. The average FeC(Cp*) bond lengths of the substituted Cp rings in the 4-bromo and 4-chloro­phenyl derivatives are identical, within experimental error, as in (I) [2.044 (13) Å]. As mentioned before, the FeC bond length where the pendant group is attached is substanti­ally shorter than the remaining FeC(Cp) distances. The same bonding pattern is also observed for the 4-bromo and 4-chloro­phenyl ferrocene­carboxyl­ates. The C(Cp)C(CO) bond length in (I), C1—C6, is shorter than a typical CC single bond, [1.473 (3) versus 1.54 Å (single bond); Pauling, 1960 ▸]. This suggests partial double-bond character and delocalization with the Cp π system in analogous manner to that for the 4-bromo and 4-chloro derivatives. In the structure of the disubstituted ferrocene Fe(C5H4CO2CH3)2, (IV) (Gao et al., 2009 ▸), the average FeC(Cp) bond lengths are 2.048 (11)/2.049 (14) Å, similar to the title complex but the Cp rings adopt almost an eclipsed conformation with a stagger angle of 2.37° (Fig. 2 ▸). In addition, the functional groups are not positioned perfectly anti to each other. The FeC(Cp)C(CO) bond in (IV) [1.477 (4) Å] is notably shorter than a typical CC single bond (1.54 Å), in a similar manner to the title complex, suggesting delocalization with the Cp π system.
Figure 2

A Newman projection of Fe(C5H4CO2CH3)2.

Finally, (I) contains two π ring systems, 4-(1H-pyrrol-1-yl)phenyl, which in principle could be involved in intra­molecular π–π or C—H⋯π stacking similar to other 1,1′-disubstituted ferrocenes with an extended π ring system (Okabe et al., 2009 ▸; Togni et al., 1994 ▸; Gelin & Thummel, 1992 ▸). However, such π–π or C—H⋯π stacking is not observed in (I) since the Cp rings adopt an anti conformation.

Synthesis and crystallization

The synthesis of (I) was accomplished by treating 1,1′-ferrocenedi­carb­oxy­lic acid with oxalyl chloride according to our recently published procedure (Pérez et al., 2015 ▸). 1H NMR (500 MHz, CDCl3) (δ p.p.m.): 7.37 (2H, d, ph; 3 J = 8.8 Hz), 7.25 (2H, d, py; 3 J = 2.8 Hz), 7.03 (2H, dd, ph; 3 J = 1.3 Hz), 6.34 (2H, dd, py; 3 J = 1.6 Hz), 5.08 (2H, overlapping doublets, AA′, Cp), 4.64 (2H, overlapping doublets, BB′, Cp). 13CNMR (125 MHz, CDCl3) (δ p.p.m.): 169.0 (C=O), 148.3, 138.6, 122.9, 121.5, 119.5, 110.5, 73.4, 72.4, 72.0. Analysis calculated for C32H24O4FeN2: C, 69.05; H, 4.40; found: C, 68.62; H, 4.46. Crystallization of (I) was performed inside an NMR tube containing CD2Cl2 for a period of two weeks, obtaining block-shaped orange crystals suitable for X-ray diffraction.

Refinement

Crystal data, data collection and structure refinement details are summarized in Table 1 ▸. H atoms were positioned in idealized locations (C(6)—H = 0.95, C(5)—H = 1.00 Å with U iso(H) = 1.2U eq(C).
Table 1

Experimental details

Crystal data
Chemical formula[Fe(C16H12NO2)2]
M r 556.38
Crystal system, space groupOrthorhombic, P b c a
Temperature (K)100
a, b, c ()10.6386(15), 7.3948(10), 30.554(4)
V (3)2403.7(6)
Z 4
Radiation typeMo K
(mm1)0.67
Crystal size (mm)0.28 0.26 0.23
 
Data collection
DiffractometerBruker APEXII CCD
Absorption correctionMulti-scan (SADABS; Bruker, 2010)
T min, T max 0.833, 0.877
No. of measured, independent and observed [I > 2(I)] reflections12444, 2999, 2247
R int 0.077
(sin /)max (1)0.669
 
Refinement
R[F 2 > 2(F 2)], wR(F 2), S 0.044, 0.117, 1.02
No. of reflections2999
No. of parameters178
H-atom treatmentH-atom parameters constrained
max, min (e 3)0.34, 0.62

Computer programs: APEX2 and SAINT (Bruker, 2010 ▸), SHELXS97 and SHELXTL (Sheldrick, 2008 ▸) and SHELXL2013 (Sheldrick, 2015 ▸).

Crystal structure: contains datablock(s) I. DOI: 10.1107/S2056989015007446/bg2552sup1.cif Structure factors: contains datablock(s) I. DOI: 10.1107/S2056989015007446/bg2552Isup2.hkl CCDC reference: 1054149 Additional supporting information: crystallographic information; 3D view; checkCIF report
[Fe(C16H12NO2)2]Dx = 1.537 Mg m3
Mr = 556.38Mo Kα radiation, λ = 0.71073 Å
Orthorhombic, PbcaCell parameters from 2807 reflections
a = 10.6386 (15) Åθ = 2.7–28.1°
b = 7.3948 (10) ŵ = 0.67 mm1
c = 30.554 (4) ÅT = 100 K
V = 2403.7 (6) Å3Block, orange
Z = 40.28 × 0.26 × 0.23 mm
F(000) = 1152
Bruker APEXII CCD diffractometer2247 reflections with I > 2σ(I)
φ and ω scansRint = 0.077
Absorption correction: multi-scan (SADABS; Bruker, 2010)θmax = 28.4°, θmin = 2.7°
Tmin = 0.833, Tmax = 0.877h = −13→14
12444 measured reflectionsk = −9→9
2999 independent reflectionsl = −37→40
Refinement on F20 restraints
Least-squares matrix: fullHydrogen site location: inferred from neighbouring sites
R[F2 > 2σ(F2)] = 0.044H-atom parameters constrained
wR(F2) = 0.117w = 1/[σ2(Fo2) + (0.047P)2 + 0.928P] where P = (Fo2 + 2Fc2)/3
S = 1.01(Δ/σ)max < 0.001
2999 reflectionsΔρmax = 0.34 e Å3
178 parametersΔρmin = −0.62 e Å3
Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell e.s.d.'s are taken into account individually in the estimation of e.s.d.'s in distances, angles and torsion angles; correlations between e.s.d.'s in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell e.s.d.'s is used for estimating e.s.d.'s involving l.s. planes.
xyzUiso*/Ueq
Fe10.50000.50000.50000.01323 (14)
O10.23108 (15)0.4748 (2)0.41347 (5)0.0213 (4)
O20.41465 (13)0.3430 (2)0.39352 (4)0.0173 (3)
N10.37269 (16)0.3889 (2)0.21120 (5)0.0133 (4)
C10.3680 (2)0.3523 (3)0.46783 (7)0.0149 (4)
C20.3145 (2)0.4294 (3)0.50667 (6)0.0169 (4)
H2A0.24150.51420.50810.020*
C30.3857 (2)0.3643 (3)0.54286 (7)0.0216 (5)
H3A0.37160.39700.57420.026*
C40.4812 (2)0.2469 (3)0.52692 (7)0.0191 (5)
H4A0.54540.18270.54510.023*
C50.4712 (2)0.2403 (3)0.48035 (7)0.0166 (4)
H5A0.52620.16930.46010.020*
C60.3264 (2)0.3975 (3)0.42318 (6)0.0144 (4)
C70.3923 (2)0.3684 (3)0.34853 (6)0.0145 (4)
C80.48316 (19)0.4601 (3)0.32540 (7)0.0155 (4)
H8A0.55020.51820.34040.019*
C90.47630 (19)0.4673 (3)0.27993 (7)0.0151 (4)
H9A0.53980.52880.26390.018*
C100.37736 (19)0.3853 (2)0.25769 (6)0.0121 (4)
C110.28353 (19)0.2994 (3)0.28206 (7)0.0149 (4)
H11A0.21370.24690.26740.018*
C120.29095 (19)0.2899 (3)0.32731 (6)0.0154 (4)
H12A0.22720.23020.34360.018*
C130.2795 (2)0.3154 (3)0.18518 (7)0.0174 (4)
H13A0.20770.25180.19540.021*
C140.3076 (2)0.3494 (3)0.14240 (7)0.0195 (5)
H14A0.25870.31530.11770.023*
C150.4232 (2)0.4449 (3)0.14143 (7)0.0213 (5)
H15A0.46610.48620.11610.026*
C160.4613 (2)0.4663 (3)0.18374 (7)0.0184 (4)
H16A0.53640.52480.19290.022*
U11U22U33U12U13U23
Fe10.0159 (2)0.0111 (2)0.0127 (2)−0.00228 (16)−0.00142 (16)0.00108 (15)
O10.0196 (9)0.0274 (8)0.0169 (8)0.0076 (7)−0.0004 (6)−0.0006 (6)
O20.0162 (8)0.0220 (8)0.0137 (7)0.0029 (6)−0.0003 (6)−0.0013 (6)
N10.0123 (8)0.0123 (8)0.0154 (8)−0.0003 (7)0.0015 (7)−0.0003 (6)
C10.0164 (10)0.0125 (9)0.0160 (10)−0.0039 (8)0.0003 (8)−0.0003 (7)
C20.0161 (10)0.0168 (10)0.0179 (10)−0.0040 (9)0.0031 (8)0.0006 (8)
C30.0292 (12)0.0190 (11)0.0165 (11)−0.0081 (10)0.0015 (9)0.0016 (8)
C40.0232 (12)0.0139 (10)0.0201 (11)−0.0055 (9)−0.0051 (9)0.0046 (8)
C50.0197 (11)0.0105 (9)0.0197 (11)−0.0009 (9)−0.0040 (9)0.0007 (8)
C60.0149 (10)0.0121 (9)0.0162 (10)−0.0015 (8)0.0004 (8)−0.0014 (7)
C70.0157 (10)0.0137 (9)0.0142 (10)0.0024 (8)−0.0008 (8)−0.0014 (7)
C80.0135 (10)0.0150 (10)0.0180 (10)−0.0025 (8)−0.0008 (8)−0.0027 (8)
C90.0127 (10)0.0135 (9)0.0192 (10)−0.0006 (8)0.0023 (8)0.0003 (8)
C100.0127 (10)0.0085 (9)0.0151 (10)0.0031 (8)0.0003 (8)−0.0006 (7)
C110.0118 (10)0.0136 (9)0.0193 (10)−0.0027 (8)−0.0012 (8)0.0004 (8)
C120.0150 (10)0.0138 (9)0.0173 (10)−0.0010 (8)0.0023 (8)0.0018 (8)
C130.0139 (10)0.0163 (10)0.0219 (11)−0.0002 (9)−0.0005 (8)−0.0016 (8)
C140.0211 (11)0.0196 (11)0.0177 (10)0.0066 (9)−0.0016 (9)−0.0022 (8)
C150.0250 (13)0.0211 (11)0.0179 (11)0.0031 (10)0.0048 (9)0.0015 (9)
C160.0161 (10)0.0176 (10)0.0217 (11)−0.0032 (9)0.0035 (9)0.0024 (8)
Fe1—C12.032 (2)C3—H3A1.0000
Fe1—C1i2.033 (2)C4—C51.428 (3)
Fe1—C52.035 (2)C4—H4A1.0000
Fe1—C5i2.035 (2)C5—H5A1.0000
Fe1—C3i2.050 (2)C7—C81.376 (3)
Fe1—C32.050 (2)C7—C121.386 (3)
Fe1—C22.051 (2)C8—C91.392 (3)
Fe1—C2i2.051 (2)C8—H8A0.9500
Fe1—C4i2.055 (2)C9—C101.392 (3)
Fe1—C42.055 (2)C9—H9A0.9500
O1—C61.201 (3)C10—C111.398 (3)
O2—C61.366 (2)C11—C121.387 (3)
O2—C71.407 (2)C11—H11A0.9500
N1—C131.382 (3)C12—H12A0.9500
N1—C161.386 (3)C13—C141.364 (3)
N1—C101.422 (3)C13—H13A0.9500
C1—C51.427 (3)C14—C151.418 (3)
C1—C21.434 (3)C14—H14A0.9500
C1—C61.473 (3)C15—C161.364 (3)
C2—C31.424 (3)C15—H15A0.9500
C2—H2A1.0000C16—H16A0.9500
C3—C41.423 (3)
C1—Fe1—C1i180.0C3—C2—Fe169.63 (13)
C1—Fe1—C541.09 (8)C1—C2—Fe168.75 (12)
C1i—Fe1—C5138.91 (8)C3—C2—H2A126.3
C1—Fe1—C5i138.91 (8)C1—C2—H2A126.3
C1i—Fe1—C5i41.09 (8)Fe1—C2—H2A126.3
C5—Fe1—C5i180.0C4—C3—C2108.66 (19)
C1—Fe1—C3i111.35 (8)C4—C3—Fe169.90 (12)
C1i—Fe1—C3i68.66 (8)C2—C3—Fe169.74 (12)
C5—Fe1—C3i111.27 (9)C4—C3—H3A125.7
C5i—Fe1—C3i68.73 (9)C2—C3—H3A125.7
C1—Fe1—C368.65 (8)Fe1—C3—H3A125.7
C1i—Fe1—C3111.34 (8)C3—C4—C5107.97 (18)
C5—Fe1—C368.73 (9)C3—C4—Fe169.54 (12)
C5i—Fe1—C3111.27 (9)C5—C4—Fe168.84 (11)
C3i—Fe1—C3180.0C3—C4—H4A126.0
C1—Fe1—C241.11 (8)C5—C4—H4A126.0
C1i—Fe1—C2138.89 (8)Fe1—C4—H4A126.0
C5—Fe1—C269.15 (9)C1—C5—C4107.75 (18)
C5i—Fe1—C2110.85 (9)C1—C5—Fe169.36 (11)
C3i—Fe1—C2139.37 (9)C4—C5—Fe170.30 (11)
C3—Fe1—C240.63 (9)C1—C5—H5A126.1
C1—Fe1—C2i138.89 (8)C4—C5—H5A126.1
C1i—Fe1—C2i41.11 (8)Fe1—C5—H5A126.1
C5—Fe1—C2i110.85 (9)O1—C6—O2123.84 (18)
C5i—Fe1—C2i69.15 (9)O1—C6—C1126.17 (19)
C3i—Fe1—C2i40.63 (9)O2—C6—C1109.97 (18)
C3—Fe1—C2i139.37 (9)C8—C7—C12120.85 (19)
C2—Fe1—C2i180.0C8—C7—O2116.66 (18)
C1—Fe1—C4i111.29 (8)C12—C7—O2122.16 (18)
C1i—Fe1—C4i68.71 (8)C7—C8—C9119.63 (19)
C5—Fe1—C4i139.13 (9)C7—C8—H8A120.2
C5i—Fe1—C4i40.87 (9)C9—C8—H8A120.2
C3i—Fe1—C4i40.56 (9)C10—C9—C8120.67 (19)
C3—Fe1—C4i139.44 (9)C10—C9—H9A119.7
C2—Fe1—C4i111.44 (9)C8—C9—H9A119.7
C2i—Fe1—C4i68.56 (9)C9—C10—C11118.55 (18)
C1—Fe1—C468.71 (8)C9—C10—N1120.40 (18)
C1i—Fe1—C4111.29 (8)C11—C10—N1121.05 (17)
C5—Fe1—C440.87 (9)C12—C11—C10120.90 (19)
C5i—Fe1—C4139.13 (9)C12—C11—H11A119.5
C3i—Fe1—C4139.44 (9)C10—C11—H11A119.5
C3—Fe1—C440.56 (9)C7—C12—C11119.31 (19)
C2—Fe1—C468.56 (9)C7—C12—H12A120.3
C2i—Fe1—C4111.44 (9)C11—C12—H12A120.3
C4i—Fe1—C4180.00 (11)C14—C13—N1108.78 (19)
C6—O2—C7119.52 (16)C14—C13—H13A125.6
C13—N1—C16107.58 (17)N1—C13—H13A125.6
C13—N1—C10126.34 (17)C13—C14—C15107.54 (19)
C16—N1—C10126.08 (18)C13—C14—H14A126.2
C5—C1—C2108.28 (18)C15—C14—H14A126.2
C5—C1—C6127.65 (19)C16—C15—C14107.2 (2)
C2—C1—C6123.89 (19)C16—C15—H15A126.4
C5—C1—Fe169.56 (12)C14—C15—H15A126.4
C2—C1—Fe170.14 (12)C15—C16—N1108.9 (2)
C6—C1—Fe1122.25 (14)C15—C16—H16A125.6
C3—C2—C1107.3 (2)N1—C16—H16A125.6
  25 in total

1.  New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors.

Authors:  M Alexandra Esteves; Osvaldo Ortet; Anabela Capelo; Claudiu T Supuran; Sérgio M Marques; M Amélia Santos
Journal:  Bioorg Med Chem Lett       Date:  2010-04-28       Impact factor: 2.823

2.  Decreasing acidity in a series of aldose reductase inhibitors: 2-Fluoro-4-(1H-pyrrol-1-yl)phenol as a scaffold for improved membrane permeation.

Authors:  Maria Chatzopoulou; Alexandros Patsilinakos; Theodosia Vallianatou; Marta Soltesova Prnova; Simon Zakelj; Rino Ragno; Milan Stefek; Albin Kristl; Anna Tsantili-Kakoulidou; Vassilis J Demopoulos
Journal:  Bioorg Med Chem       Date:  2014-02-26       Impact factor: 3.641

3.  Water stability and cytotoxic activity relationship of a series of ferrocenium derivatives. ESR insights on the radical production during the degradation process.

Authors:  Giovanni Tabbì; Claudio Cassino; Giorgio Cavigiolio; Donato Colangelo; Annalisa Ghiglia; Ilario Viano; Domenico Osella
Journal:  J Med Chem       Date:  2002-12-19       Impact factor: 7.446

4.  Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).

Authors:  Michael P Clark; Kelly M George; Roger G Bookland; Jack Chen; Steven K Laughlin; Kumar D Thakur; Wenlin Lee; Jan R Davis; Ed J Cabrera; Todd A Brugel; John C VanRens; Matthew J Laufersweiler; Jennifer A Maier; Mark P Sabat; Adam Golebiowski; Vijay Easwaran; Mark E Webster; Biswanath De; George Zhang
Journal:  Bioorg Med Chem Lett       Date:  2006-12-09       Impact factor: 2.823

Review 5.  Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects.

Authors:  Anne Vessières; Siden Top; Wolfgang Beck; Elizabeth Hillard; Gérard Jaouen
Journal:  Dalton Trans       Date:  2005-09-27       Impact factor: 4.390

Review 6.  A glance at adenosine receptors: novel target for antitumor therapy.

Authors:  Stefania Merighi; Prisco Mirandola; Katia Varani; Stefania Gessi; Edward Leung; Pier Giovanni Baraldi; Mojgan Aghazadeh Tabrizi; Pier Andrea Borea
Journal:  Pharmacol Ther       Date:  2003-10       Impact factor: 12.310

Review 7.  Cisplatin nephrotoxicity: mechanisms and renoprotective strategies.

Authors:  N Pabla; Z Dong
Journal:  Kidney Int       Date:  2008-02-13       Impact factor: 10.612

8.  Ferricenium complexes: a new type of water-soluble antitumor agent.

Authors:  P Köpf-Maier; H Köpf; E W Neuse
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

9.  Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.

Authors:  Siden Top; Anne Vessières; Guy Leclercq; Jacques Quivy; J Tang; J Vaissermann; Michel Huché; Gérard Jaouen
Journal:  Chemistry       Date:  2003-11-07       Impact factor: 5.236

10.  Synthesis, structure, electrochemistry, and cytotoxic properties of ferrocenyl ester derivatives.

Authors:  Li Ming Gao; Ramón Hernández; Jaime Matta; Enrique Meléndez
Journal:  Met Based Drugs       Date:  2009-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.